{"id":955444,"date":"2026-04-28T09:06:31","date_gmt":"2026-04-28T13:06:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-reports-breakthrough-93-response-rate-in-ultrasome-knee-osteoarthritis-program-expanding-celz-201-platform-into-scalable-cell-free-regenerative-the\/"},"modified":"2026-04-28T09:06:31","modified_gmt":"2026-04-28T13:06:31","slug":"creative-medical-technology-holdings-inc-reports-breakthrough-93-response-rate-in-ultrasome-knee-osteoarthritis-program-expanding-celz-201-platform-into-scalable-cell-free-regenerative-the","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-reports-breakthrough-93-response-rate-in-ultrasome-knee-osteoarthritis-program-expanding-celz-201-platform-into-scalable-cell-free-regenerative-the\/","title":{"rendered":"Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome\u2122 Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies"},"content":{"rendered":"
\n

\n Ultrasome\u2122 Demonstrates Strong Clinical Signal While Leveraging GMP-Produced <\/em>
\n CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market<\/em>\n <\/p>\n

PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)<\/strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome\u2122, the Company\u2019s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.<\/p>\n

The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported.<\/p>\n

Ultrasome\u2122 is derived from the Company\u2019s GMP-manufactured cell therapy product CELZ-201 (Olastrocel), which is currently being evaluated in the Company\u2019s FDA-cleared ADAPT clinical trial. This relationship establishes a direct connection between CELZ\u2019s clinical-stage biologic platform and its next-generation cell-free regenerative strategy, expanding the potential applications of CELZ-201 into broader, high-volume indications.<\/p>\n

\n Platform Expansion: Extending CELZ-201 into Cell-Free Regenerative Therapies with Ultrasome\u2122<\/strong>\n <\/p>\n

Creative Medical is leveraging the biological signaling components of CELZ-201 in a cell-free format, enabling scalable manufacturing, reduced cost of production, off-the-shelf availability, and simplified execution across outpatient settings. Ultrasome\u2122 is designed to address osteoarthritis through targeted modulation of inflammatory signaling, suppression of cartilage degradation, and promotion of regenerative activity.<\/p>\n

\u201cThis represents a significant evolution of our platform,\u201d said Timothy Warbington, President and CEO. \u201cBy building on CELZ-201, we are advancing a cell-free regenerative approach that improves scalability and accessibility.\u201d<\/p>\n

\n A Large, Underserved Market with Clear Differentiation<\/strong>
\n
Osteoarthritis affects over 30 million adults in the United States and represents a significant multi-billion-dollar opportunity. Current treatments are limited to symptom management and invasive procedures.<\/p>\n

\n What Comes Next<\/strong>
\n
Following these positive pilot results, Creative Medical plans to:<\/p>\n